Universal Ibogaine Inc. (TSXV:IBO)

Market Cap	1.56M -49.3%
Revenue (ttm)	2.06M -11.7%
Net Income	-1.48M
EPS	-0.01
Shares Out	312.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,660,150
Average Volume	241,304
Open	0.0050
Previous Close	0.0100
Day's Range	0.0050 - 0.0050
52-Week Range	0.0050 - 0.0450
Beta	5.47
RSI	42.68
Earnings Date	Nov 28, 2025

About Universal Ibogaine

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Karos
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: IBO

Financial Performance

In fiscal year 2024, Universal Ibogaine's revenue was 2.33 million, an increase of 126.32% compared to the previous year's 1.03 million. Losses were -2.05 million, -14.17% less than in 2023.